Asia
Tanvex Biopharma Approves 99.4% Capital Reduction to Offset Losses
Tanvex Biopharma (TPE:6541) approved a major capital restructuring plan to offset accumulated losses, involving a sharp reduction of its share capital, according to a Monday Taiwan Exchange filing.The company will cancel 249.6 million common shares, equivalent to a 99.40% cut, reducing paid-in capital from NT$2.49 billion to NT$15 million.Tanvex said the move will strengthen its financial structure and align with group operations, the filing said.
TPE:6541
